1
M
aterials
D
esign
A
nalysis
R
eporting (MDAR)
Checklist for Authors
The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life scien
ces
(see Statement of Task:
doi:10.31222/osf.io/9sm4x.
). The
MDAR checklist is a tool for authors, editors
,
and others seeking to adopt
the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document
for additional context for the MDAR framework.
2
For
all that apply, please note where in the manuscript the required information is provided.
Materials
:
Newly created materials
indicate where provided: page no/section/legend)
n/a
The manuscript includes a dedicated "materials
availability statement" providing transparent
disclosure about availability of newly created
m
aterials including details on how materials
c
an be
accessed and describing any restrictions on access.
n/a
Antibodies
indicate where provided: page no/section/legend)
n/a
For commercial reagents, provide supplier name,
catalogue number and
RRID
, if available.
n/a
DNA and RNA sequences
indicate where
provided: page no/section/legend)
n/a
Short novel DNA or RNA including primers, probes
:
Sequences should be included or deposited in a
public repository.
n/a
Cell materials
indicate where provided: page no/section/legend
n/a
Cell lines:
Provide species information, strain.
Provide accession number in repository
OR
supplier
name, catalog number, clone number,
OR
RRID.
Section: Materials and Methods.
Subsection:
In vitro cellular and tissue studies
;
Animal
studies
.
Primary cultures:
Provide species, strain, sex of
origin, genetic modification status.
n/a
Experimental animals
indicate where provided: page no/section/legend)
n/a
Laboratory animals
or Model organisms
:
Provide
species, strain, sex, age, genetic modification
status
.
Provide
a
ccession number in repository
OR
supplier
name, catalog number, clone number,
OR
RRID.
Section: Materials and Methods.
Subsection:
Animal studies
.
Animal observed in or captured from the field:
Provide species, sex, and age where
possible.
n/a
Plants and microbes
indicate where provided: page no/section/legend)
n/a
Plants:
provide species and strain,
ecotype and
cultivar where relevant,
unique accession number if
available, and source (including location for collected
wild
specimens).
n/a
Microbes:
provide species and strain, unique
accession number if available, and source.
n/a
Human research participants
indicate where provided: page no/section/legend) or
state if these demographics were not collected
n/a
If
collected and within the bounds of privacy
constraints report on age
,
sex and gender or
ethnicity for all study participants.
n/a
3
Design
:
Study protocol
indicate where provided: page no/section/legend)
n/a
If study protocol has been pre
-
registered, provide
DOI.
For clinical trials, provide the trial registration
number
OR
cite DOI.
Laboratory protocol
indicate where provided: page no/section/legend)
n/a
Provide DOI
OR
other citation details if detailed step
-
by
-
step protocols are available.
Section: Materials and Methods.
Subsection:
Animal studies
.
P
rotocol No. IA23
-
1800 and No. IA23
-
1859
Experimental study design (statistics details)
For in vivo studies
:
State whether and how the
following have been done
indicate where provided: page no/section/legend. If it
could have been done, but was not, write not done
n/a
Sample size determination
Yes, power calculations were
performed
prior to the
data
collection.
Section: Materials and Methods.
Subsection:
Animal studies
(
P
rotocol No. IA23
-
1859
).
Randomisation
Section: Materials and Methods.
Subsection:
Animal studies
.
A
fter the tumor inoculations (Day 0), the mice were
randomly divided into 4
treatment groups (n = 3), and
the treatment started.
Blinding
n/a
Inclusion/exclusion criteria
n/a
Sample definition and in
-
laboratory replication
indicate where provided: page no/section/legend
n/a
State number of times the experiment was
replicated in laboratory
.
Figure
caption
Define whether data describe technical or biological
replicates
.
Section: Materials and Methods.
Subsection:
Statistical analysis
.
Ethics
indicate where provided: page no/section/legend
n/a
Studies
involving human participants:
State details
of authority granting ethics approval (IRB or
equivalent committee(s), provide reference number
for approval.
n/a
Studies involving experimental animals:
State
details of authority granting ethics approval (IRB or
equivalent committee(s), provide reference number
for approval.
Section: Materials and Methods.
Subsection:
Animal studies
(
P
rotocol No. IA23
-
1859
).
Studies involving specimen and field
samples:
State
if relevant permits obtained, provide details of
authority approving study; if none were required,
explain why.
n/a
Dual Use Research of Concern (DURC)
indicate where provided: page no/section/legend
n/a
If
study is subject to dual use research of
concern
regulations
, state
the authority granting approval
and reference number for the regulatory approval.
n/a
Section: Materials
and
Methods.
Subsection:
Bubble life span of
BAM
s (Protocol
No.
IR24-0892
).
4
Analysis
:
Attrition
indicate where provided: page no/section/legend
n/a
Describe
whether exclusion criteria were
preestablished. Report if sample or data points were
omitted from analysis. If yes report if this was due to
attrition or intentional exclusion and provide
justification.
n/a
Statistics
indicate where provided: page
no/section/legend
n/a
Describe statistical tests used and justify choice of
tests.
Section: Materials and Methods.
Subsection:
Statistical analysis
.
Data availability
indicate where provided: page no/section/legend
n/a
For newly created and reused
datasets, the
manuscript includes a data availability statement
that provides details for access or notes restrictions
on access.
All data needed to support the conclusions of this
manuscript are included in the main text or
Supplementary Materials.
If newly created
data
sets
are publicly available,
provide accession number in repository
OR
DOI
OR
URL and licensing details where available.
n/a
If
reused data is
publicly available provide accession
number in repository
OR
DOI
OR
URL,
OR
citation.
n/a
Code availability
indicate where provided: page no/section/legend
n/a
For all newly generated custom computer
code/software/mathematical algorithm or re
-
used
code essential for replicating the main findings of
the study, the
manuscript includes a data availability
statement that provides details for access or notes
restrictions.
All data needed to support the conclusions of this
manuscript are included in the main text or
Supplementary Materials.
Code
is available upon
request
to the
corresponding author.
If newly generated code is publicly available, provide
accession number in repository,
OR
DOI
OR
URL and
licensing details where available. State any
restrictions on code availability or accessibility.
n/a
If reused code is
publicly available provide accession
number in repository
OR
DOI
OR
URL,
OR
citation.
n/a
5
Reporting
MDAR framework recommends adoption of discipline
-
specific guidelines, established
and endorsed through community
initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.
Adherence to community standards
indicate where provided: page no/section/legend
n/a
State if relevant guidelines (e.g., ICMJE, MIBBI,
ARRIVE) have been followed, and whether a checklist
(e.g., CONSORT, PRISMA, ARRIVE) is provided with
the manuscript.
n/a